Intraoperative EEG Monitoring and Postoperative Delirium in Elderly Patients With Sevoflurane Anesthesia

Effects of Different Sevoflurane Concentrations on Intraoperative EEG and Postoperative Delirium in Elderly Patients

Delirium is an acute onset of attentional and cognitive impairment. BIS guided anesthesia can reduce the incidence of postoperative delirium. Long term electroencephalogram (EEG) suppression during operation is related to postoperative delirium. The latest research shows that the anesthesia depth guided by EEG does not reduce the incidence of postoperative delirium. The purpose of this study was to explore the relationship between anesthesia exposure with different minimum alveolar concentration(MAC) and postoperative delirium(POD), and to observe the characteristics of EEG.

Study Overview

Detailed Description

More and more studies have focused on the relationship between EEG inhibition and postoperative delirium in general anesthesia. At present, there are two kinds of commonly processed quantitative EEG monitoring to evaluate the depth of anesthesia, one is bispectral index (BIS) and the other is patient state index (PSI). The relationship between intraoperative anesthetic exposure and postoperative delirium is unclear, or whether potential patient characteristics increase the risk of EEG suppression and postoperative delirium.

Gastrointestinal surgery can lead to long-term changes in colonic flora, which can remotely regulate brain function through the gut brain axis. We speculated that the abnormal composition of intestinal flora before abdominal operation might be the influencing factor of POD.

Study Type

Interventional

Enrollment (Actual)

460

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Study Locations

    • Anhui
      • Hefei, Anhui, China, 230022
        • The First Affiliated Hospital of Anhui Medical University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years to 90 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Clinical diagnosis of gastrointestinal diseases
  • Patients were aged 60 to 90 years
  • American Society of Anesthesiologists (ASA) risk classification II-IV
  • Patients were scheduled to undergo elective major abdominal operation(with a anticipated time of 2-6 h)

Exclusion Criteria:

  • Preoperative dementia or cognitive impairment
  • Mental instability or mental illness
  • Patients with any factors affecting cognitive assessment, such as language, vision and hearing impairment
  • Any cerebrovascular accident occurred within 3 months, such as stroke etc
  • Previous history of delirium
  • Known hypersensitivity to sevoflurane or history of malignant hyperthermia
  • Abuse of narcotic sedative and analgesic drugs
  • Those who have reoperation within 7 days after operation

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: light general anesthesia
During anesthesia maintenance, patients were received with low concentration sevoflurane to maintain a target of 0.8 MAC.
To maintain a target of sevoflurane inhalation concentration 0.8 MAC.
Experimental: deep general anesthesia
During anesthesia maintenance, patients were received with high concentration sevoflurane to maintain a target of 1.0 MAC.
To maintain a target of sevoflurane inhalation concentration 1.0 MAC.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of POD
Time Frame: The 1st day after the surgery
Incidence of POD after surgery
The 1st day after the surgery
Incidence of POD
Time Frame: The 2nd day after the surgery
Incidence of POD after surgery
The 2nd day after the surgery
Incidence of POD
Time Frame: The 3rd day after the surgery
Incidence of POD after surgery
The 3rd day after the surgery
Incidence of POD
Time Frame: The 5th day after the surgery
Incidence of POD after surgery
The 5th day after the surgery
Incidence of POD
Time Frame: The 7th day after the surgery
Incidence of POD after surgery
The 7th day after the surgery

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
EEG burst inhibition
Time Frame: During surgery
Frequency of EEG burst inhibition
During surgery
EEG burst inhibition
Time Frame: During surgery
Duration of EEG burst inhibition
During surgery
Incidence of adverse events
Time Frame: 30-day after surgery
Incidence of adverse events after surgery
30-day after surgery
length of stay
Time Frame: From 1st day after the surgery to 2 weeks
length of stay after surgery
From 1st day after the surgery to 2 weeks
30-day mortality
Time Frame: 30-day after surgery
30-day mortality after surgery
30-day after surgery

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 1, 2020

Primary Completion (Actual)

January 30, 2023

Study Completion (Actual)

February 10, 2023

Study Registration Dates

First Submitted

January 8, 2020

First Submitted That Met QC Criteria

February 29, 2020

First Posted (Actual)

March 3, 2020

Study Record Updates

Last Update Posted (Actual)

February 24, 2023

Last Update Submitted That Met QC Criteria

February 23, 2023

Last Verified

March 1, 2022

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Postoperative Delirium

Clinical Trials on Low MAC

3
Subscribe